These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 14584299)

  • 21. [Diabetic nephropathy].
    Morcos M; Zeier M; Schwenger V
    Dtsch Med Wochenschr; 2007 May; 132(19):1039-42. PubMed ID: 17476634
    [No Abstract]   [Full Text] [Related]  

  • 22. [Type 2 diabetic patient with kidney damage. Sartans banish dialysis risk].
    MMW Fortschr Med; 2004 Jul; 146(27-28):56. PubMed ID: 15526676
    [No Abstract]   [Full Text] [Related]  

  • 23. Can risk factor modification prevent nephropathy in type 2 diabetes mellitus?
    Wesson DE
    Am J Kidney Dis; 2000 Nov; 36(5):1054-6. PubMed ID: 11054366
    [No Abstract]   [Full Text] [Related]  

  • 24. Chronic kidney disease. Avoiding the point of no return.
    Compton A
    Adv Nurse Pract; 2004 Jun; 12(6):75-8. PubMed ID: 15218593
    [No Abstract]   [Full Text] [Related]  

  • 25. Fighting diabetic kidney disease. The best defense is a good offense--take action now to prevent kidney disease.
    Hirsch IB
    Diabetes Forecast; 2002 Feb; 55(2):68-70. PubMed ID: 14959672
    [No Abstract]   [Full Text] [Related]  

  • 26. The authors reply:
    Perkovic V; Woodward M; Zoungas S; Chalmers J
    Kidney Int; 2013 Sep; 84(3):622. PubMed ID: 23989363
    [No Abstract]   [Full Text] [Related]  

  • 27. Diabetic nephropathy.
    Ritz E
    Saudi J Kidney Dis Transpl; 2006 Dec; 17(4):481-90. PubMed ID: 17186681
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Kidney disease ups heart risk: here's help.
    Johns Hopkins Med Lett Health After 50; 2007 Jan; 18(11):3, 7. PubMed ID: 17323492
    [No Abstract]   [Full Text] [Related]  

  • 29. Recent advances in diabetic nephropathy.
    Marshall SM
    Postgrad Med J; 2004 Nov; 80(949):624-33. PubMed ID: 15537844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Understanding the long-term benefits and dangers of intensive therapy of diabetes.
    Nathan DM
    Arch Intern Med; 2012 May; 172(10):769-70. PubMed ID: 22636821
    [No Abstract]   [Full Text] [Related]  

  • 31. Diabetic kidney disease: act now or pay later.
    Atkins RC; Zimmet P
    Nephron Clin Pract; 2010; 114(3):4 p preceding c165. PubMed ID: 20201160
    [No Abstract]   [Full Text] [Related]  

  • 32. Rationale for and study design of the sulodexide trials in Type 2 diabetic, hypertensive patients with microalbuminuria or overt nephropathy.
    Lambers Heerspink HJ; Fowler MJ; Volgi J; Reutens AT; Klein I; Herskovits TA; Packham DK; Fraser IR; Schwartz SL; Abaterusso C; Lewis J;
    Diabet Med; 2007 Nov; 24(11):1290-5. PubMed ID: 17956455
    [TBL] [Abstract][Full Text] [Related]  

  • 33. World Kidney Day 2010: diabetic kidney disease--act now or pay later.
    Atkins RC; Zimmet P
    Am J Kidney Dis; 2010 Feb; 55(2):205-8. PubMed ID: 20116679
    [No Abstract]   [Full Text] [Related]  

  • 34. Prevention and treatment of diabetic nephropathy.
    Wittmann I; Molnár GA; Degrell P; Wagner Z; Tamaskó M; Laczy B; Brasnyó P; Wagner L; Nagy J
    Diabetes Res Clin Pract; 2005 Jun; 68 Suppl1():S36-42. PubMed ID: 15955373
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Caution advised in interpreting nonsignificant results from ADVANCE post hoc analysis.
    Brar JE
    Kidney Int; 2013 Sep; 84(3):621-2. PubMed ID: 23989359
    [No Abstract]   [Full Text] [Related]  

  • 36. Prioritizing treatments in type 2 diabetes mellitus.
    Margolis KL; O'Connor PJ
    Arch Intern Med; 2012 May; 172(10):770-2. PubMed ID: 22636822
    [No Abstract]   [Full Text] [Related]  

  • 37. Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension.
    Bakris GL; Toto RD; McCullough PA
    J Hum Hypertens; 2005 Feb; 19(2):139-44. PubMed ID: 15457206
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of periodontitis on overt nephropathy and end-stage renal disease in type 2 diabetes: response to Shultis et al.
    Varon FN
    Diabetes Care; 2007 Dec; 30(12):e138; author reply e139. PubMed ID: 18042747
    [No Abstract]   [Full Text] [Related]  

  • 39. Effects of gender, Helicobacter pylori and hepatitis B virus serology status on cardiovascular and renal complications in Chinese type 2 diabetic patients with overt nephropathy.
    Lo MK; Lee KF; Chan NN; Leung WY; Ko GT; Chan WB; So WY; Ng MC; Ho CS; Tam JS; Lam CW; Tong PC; Chan JC
    Diabetes Obes Metab; 2004 May; 6(3):223-30. PubMed ID: 15056131
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of losartan on the lifetime incidence of ESRD and costs in Mexico.
    Arredondo A; Burke TA; Carides GW; Lemus E; Querol J
    Rev Invest Clin; 2005; 57(3):399-405. PubMed ID: 16187699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.